Autres langues Arcoma AB

Actions

ARCOMA

SE0006219176

Equipement et technologie médicale avancés

Temps Différé Nasdaq Stockholm 11:10:21 17/09/2026			Varia. 5j.	Varia. 1 janv.
7,720 ^SEK	-5,85%		-7,43%	+5,18%

20/08	Arcoma AB publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
12/05	Arcoma : le directeur financier Johan Dahlberg annonce son départ	RE

Autres langues

20/08	Arcoma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
01/07	Arcoma: Discontinuation of coverage
12/05	Arcoma Johan Dahlberg to leave as CFO
11/05	Arcoma gets order for 7 x-ray systems in US
24/04	Arcoma: Market turmoil delays recovery – Q1 review
23/04	Arcoma Q1 Ebitda down at SEK 2.5 million
23/04	Arcoma AB Reports Earnings Results for the First Quarter Ended March 31, 2026
21/04	Sweden's Arcoma Names Chief Technology Officer
13/02	Arcoma: Going into 2026 with favourable comparables – Q4 review
12/02	Arcoma Q4 net sales SEK 34.7 mln
12/02	Arcoma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025
09/02	Arcoma: Awaiting a market recovery in Europe – Q4 preview
24/10/25	Arcoma: Europe muted, business mix supports margins – Q3 review
23/10/25	Arcoma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
23/10/25	Arcoma Q3 net sales flat at SEK 29.9 million
13/10/25	Arcoma: Sequential improvements but US uncertainty – Q3 preview
22/08/25	Arcoma: US remains muted, easier comparisons in H2 – Q2 review
21/08/25	Arcoma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
21/08/25	Arcoma Q2 Net Sales At SEK 31.4 MLN
08/07/25	Arcoma: Directed share issue, US to remain muted – Q2 preview
24/06/25	Arcoma AB successfully completes directed share issue of SEK 11.0 million (~ EUR 1 million) (MAR)
29/04/25	Arcoma: Solid gross margin, North America revenue declines – Q1 review
29/04/25	Arcoma Q1 EBITDA Lowers To SEK 4.5 Mln
29/04/25	Arcoma AB Reports Earnings Results for the First Quarter Ended March 31, 2025
14/02/25	Arcoma: Margins expand, but Europe remains under pressure – Q4 review